Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1371591 | Bioorganic & Medicinal Chemistry Letters | 2010 | 6 Pages |
Abstract
A series of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives was optimized as Polo-like kinase 1 inhibitors. Extensive SAR afforded a highly potent and selective PLK1 compound. The compound showed good antiproliferative activity when tested in a panel of tumor cell lines with PLK1 related mechanism of action and with good in vivo antitumor efficacy in two xenograft models after iv administration.
Graphical abstractA 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline series of Polo-like kinase inhibitors is reported and the SAR disclosed. The series led to low nanomolar PLK1 inhibitors. Compound 4 was tested in vivo showing good antitumor efficacy after iv administration.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Italo Beria, Barbara Valsasina, Maria Gabriella Brasca, Walter Ceccarelli, Maristella Colombo, Sabrina Cribioli, Gabriele Fachin, Ronald D. Ferguson, Francesco Fiorentini, Laura M. Gianellini, Maria L. Giorgini, Jurgen K. Moll, Helena Posteri,